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Renal artery stenosis 
and· hypertension 
Whom and how to screen 
and treat 
Patients with renal artery stenosis are at high risk of cardiovascular events. Aggressive 
medical therapy to lower cardiovascular risk is the first priority in these patients; 
endovascular treatment is required in only a few carefully selected cases. 
Renovascular disease, often presenting in the 
patient with vascular disease and no other symp-
toms, has been coDsidered a common and poten-
tially treatable cause of secondary hypertension. 
However, whether medical therapy or endovascu-
lar treatment is the optimal strategy for patients 
with renovascular disease has been an area of 
contention. Recent evidence now suggests that 
the benefit of angioplasty of the renal arteries may 
be limited to selected patients. 
The scope of this review is to direct clinicians to 
the groups of patients who may require screening, 
to discuss the appropriate modalities of screening 
and to consider the selection of patients for inter-
vention in addition to the successful medical 
management that currently occurs. 
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Who develops renal artery stenosis? 
The following case is typical of a patient who may 
present in general practice and in whom a diagno-
sis of renal artery stenosis (RAS; Figure 1) should 
be considered. Comments on the appropriate 
assessment and treatment of this patient are dis-
cussed later in the article. 
Case study 
A 75-year-old man comes to your practice with 
a blood pressure of 160/70 mmHg. He has been a 
smoker, had high lipid levels and had poorly con-
trolled hypertenskm for.the past 10 years despite 
taking four antihypertensive agents. 
Clinical examination demonstrates carotid 
bruits, no renal bruits and a fourth heart sound. 
His serum creatinine level is 150 pmol!L (estimated 
glomerular filtration rate [eGFR] 45 mUmin) and 
urinalysis shows 1 +protein. 
· The ultrasound of his renal tract shows a dis-
crepancy in renal size (right 10 em; left 7.8 em) and 
a suggestion of increased velocity in the renal artery 
of the smaller kidney; however, there is too much 
interference to make any significant conclusion 
about the presence ofRAS. 
How should this patient be further evaluated 
and treated? 
Aetiology of renal artery stenosis 
With the increasing incidence of hypertension, 
chronic kidney disease (CKD and/or diabetes 
in our population, the finding of atherosclerotic 
disease of the cerebral and coronary vessels in 
patients with these conditions is expected. How-
ever, we now know that there is a high likelihood 
that such patients will also have renal artery athero-
sclerotic disease. 
Studies from the 1%0s and 1970s showed that 
270.4> of patients over 50 years of age had more than 
50% stenosis of their renal artery (autopsy data) 
and up to 6% of cohorts with hypertension under-
going arteriography had RAS. In patients with 
refractory hypertension, between 20 and 40% of 
unselected subjects have been shown to have .RAS.' 
There is evidence that RAS is progressive, with 
studies conducted prior to interventions or medical 
treatments (such as statins) estimating a 14 to 39% 
progression oflesions over one to six years.z A 
clearer understanding of accurate progression rates 
is difficult to obtain because this atherosclerotic 
population has a high mortality rate. In the recent 
Angioplasty and Stenting for Renal Artery Lesions 
(ASTRAL) study, 26% of patients with athero-
sclerotic renovascular disease died from a cardio-
vascular event during the five-year study duration/ 
Classification of renovascular disease 
Renovascular hypertension is systemic hypertension 
due to narrowing of the renal arteries. Although 
large and small (that is, intrarenal) vessel disease can 
exist, from a haemodynamic point of view, a prox-
imal stenosis is significant when there is a pressure 
gradient across the stenosis. This pressure gradient 
triggers intrarenal adaptive mechanisms distally, 
leading to renal ischaenua and hypertension. The 
presence of coexistent small vessel disease will ren-
der the kidney nonresponsive to revascularisation. 
RAS has two main aetiologies: atherosclerosis 
and fibromuscular dysplasia. Atherosclerosis 
accounts for 70 to 90% of cases ofRAS and usually 
involves the ostium and proximal third of the main 
renal artery! Fibromuscular dysplasia is a collection 
of vascular diseases that affects the intima, media 
and adventitia and is responsible for 10 to 30% 
of cases ofRAS.5 
Despite the many studies in the literature, 
there is no unifying classification of the degrees of 
stenosis versus severity and outcome. At least a 
50% narrowing is necessary to produce a pressure 
gradient as mentioned above, as shown by a study 
combining three-dimensional magnetic resonance 
angiography (MRA) and direct measurements 
Figure 1. Spiral oomputed 
tomography angiogram 
showing severe stenosis 
of the left renal artery. 
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Renal artery stenosis and hypertension 
continued 
across a stenotic lesion.~ Despite a lack of 
consensus, most authors use a reduction 
in luminal diameter of 50% as a cut-off 
point to define the presence of haemo-
dynamically significant RAS.~ In the 
soon to be published Caring for Aus-
tralasians with Renovascular Disease 
(CARl) guidelines, the following classifi-
cation has been devised based on the 
likelihood of progression:' 
• less than 50% stenosis: insignificant 
• 50 to 70% stenosis: moderate 
• more than 70% stenosis: severe. 
Diagnosis and assessment 
Although all the imaging modalities used 
to investigate RAS have improved over 
the past decade, they do have potential 
side effects, which must be considered 
when selecting the most appropriate 
investigation for each patient Addition-
ally, in groups in whom significant harm 
is possible from undergoing screening 
diagnostic tests, there is the principal 
that any tests should be performed only 
in those who have a high pretest probabil-
ity of having the disease. In the context 
of RAS, such patients may have impaired 
renal function, hypertension requiring 
more than four antihypertensive agents, 
diabetes or vasculopathy, or a renal bruit 
Case study continued 
The patient has had refractory hyperten-
sion for many years, and investigations 
have revealed that the renal vascular bed 
is affected with a shrunken kidney (likely 
from ischaemia) and proteinuria of a level 
consistent with vascular disease. Although 
it is possible that this patient might experi-
ence side effects from imaging, he has a 
high pretest probability ofhaving RAS and 
should therefore be fUrther investigated. 
Which imaging test to use? 
The reported diagnostic accuracles of the 
different imaging tests used to investigate 
the renal arteries overlap, and the sensi-
tivities and specificlties of these tests vary 
according to methodological issues, spe-
cific patient groups and gold standard 
comparisons. The selection of the diag-
nostic test will depend on local resources 
available, cost and local expertise and 
experience, in addition to patient factors. 
Duplex ultrasonography 
The least invasive test is duplex ultra-
sonography, which, in the hands of teams 
with technical e:xpertise, is a useful screen-
ing tooL Unfortunately, subsequent tests 
are often required because of the high 
rate of false-positive and false-negative 
results. Of note, the sensitivity and speci-
ficity of ultrasonography vary depending 
on the skill of the laboratory, and gener-
ally this investigation is of limited use in 
obese individuals. The calculation of 
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the renal resistive index (RI) may predict 
the response to revascularisation - for 
example, a low RI indicates a healthy 
kidney distal to a stenosis. 
Intra-arterial digital subtraction 
angiography 
Intra -arterial digital subtraction angiog-
raphy (IA-DSA) is regarded as the defini-
tive tool to diagnose the presence of RAS. 
It is the only investigation that directly 
measures the lumen size of the renal artery 
and can measure a pressure gradient across 
most lesions. However, it is invasive, does 
not establish the functional nature of the 
stenotic lesion, and the degree of stenoses 
may be subject to substantial interobserver 
variations. In patients with large athero-
sclerotic burden, the significant complica-
tion of cholesterol embolic syndrome can 
result 
Renal sdntigraphy 
Renal scintigraphy is no longer recom-
mended for the diagnosis of RAS based 
on its poor accuracy and the promised 
functional benefits in trials have not 
resulted in better outcomes in either treat-
mentor diagnosis. 
Spiral computed tomography 
angiography 
It is reasonable to recommend spiral com-
puted tomography angiography (spiral 
CTA). as an accurate, minimally invasive 
screening test especially suited to the 
diagnosis of RAS due to fibromuscular 
dysplasia. However, in patients who have 
moderate CKD (eGFR <60 mUmin) or 
more severe CKD, prehydration with intra-
venous saline (with or without n-acetyl 
cysteine or sodium bicatbonate) should be 
used to reduce the incidence of contrast 
nephropathy. If contrast nephropathy 
develops, management is expectant, and 
dialysis is rarely required. Usually renal 
function recovers fully, although it is 
not uncommon to observe some loss of 
GFR in patients with underlying CKD 
secondary to the contrast insult 
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Renal artery stenosis and hypertension 
continued 
Gadolinium-enhanced MRA 
Gadolinium-enhanced MRA is highly sensitive in detecting 
atherosclerotic RAS and has significantly higher accuracy than 
any other modality in excluding the disease. The use of gadolin-
ium in patients with eGFR1ess than 30 mUmin should be avoided 
in view of the mk of the relatively recently described nephrogenic 
systemic fibrosis, which is most likely to occur with repeated doses 
of gadolinium in patients with end-stage kidney disease. Nephro-
genic systemic fibrosis is an illness causing fibrosis of skin and 
other tissues (not unlike sclerodenna) and may not be reversible. 
Case study continued 
If the resources were available, the specialist would most likily 
consider spiral CI'Afor this patient or move directly tv IA-DSA 
because he has poorly controlled hypertension. 
What to do when renal artery stenosis is diagnosed'? 
Patients with renovascular disease have a markedly increased risk 
of coronary events, stroke, heart failure and death. Indeed, the . 
risk of these events is significandy greater than the risk of pro-
gression to end-stage kidney disease. Although the immediate 
concern in patients with RAS is the control of blood pressure, 
overall cardiovascular mortality needs to be reduced. Aggressive 
medical therapy to reduce this risk is the first priority and sup-
ported bythe evidence.1" Referral to a renal specialist (or a similar 
hypertension specialist) fur consideration of the involvement of 
interventional vascular clinicians is required in only a few selected 
cases (see the Table). There is no indication for recurrent imaging 
to follow renal size or the degree of stenosis. Knowledge of any 
progression of a stenosis does not dictate the required intervention. 
However, vascular physicians may organise follow-up imaging 
fur patients with stented arteries at six months then yearly. 
Diet and lifestyle 
As in patients with other vascular diseases, salt restriction, weight 
loss, physical activity and cigarette cessation are likely to benefit 
patients with RAS by reducing their overall cardiovascular risk. 
In the recent ASTRAL study, patients with any degree of RAS 
(vascular burden) had a high mortality, probably secondary to 
uncontrolled hypertension or the existence of vascular diseaSe in 
other beds.' 
Medical therapy 
In patients with unilateral RAS, angiotensin converting enzyme 
(ACE) inhibitors and angiotensin receptor blockers (ARBs) are 
useful fur their ability to improve blood pressure and their overall 
cardiovascular benefit A small initial rise in serum creatinine (less 
than 300k) is usually transient (i.e. occurring for less than three 
months) and acceptable.5 
Bilateral RAS is considered a contraindication to the use of 
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Diagnosing and managing renal artery stenosis (RAS)1,. 
Patient presents with suspected RAS 
-llONS: ACE = angiotensil converting enzyme; ARB; angiotensin receptor blocker; CT = computed tomog:rapty; MRA = magnetb resonance ~~~glogi"I!Piv. 
ACE inhibitors and ARBs. Acute renal 
failure occurs in about 30% of patients 
with bilateral RAS but is usually rever-
sible. Initiation of ACE inhibitor or ARB 
therapy in such patients would usually 
be undertaken in hospital and in patients 
in whom the benefit would be very high 
(for example, in those with congestive 
heart failure).7 It is essential that renal 
function is monitored if ACE inhibitors or 
ARBs are used in patients with bilateral 
RAS (greater than 60%) or in patients 
with RAS (greater than 60%) to a solitary 
functioning kidney. This includes initial 
testing at five and seven days and then two 
weeks after the initiation of a low dose of 
the medication. 
Generally, ACE inhtbitors should be 
used before ARBs in view of the large body 
of evidence fur ACE inlubitors in many 
vascular disease states, and their lower cost 
However, evidence for the use of ARBs in 
reducing mortality from cardiovascular 
disease is accumulating. 
No other agents have been shown 
specifically to be as beneficial as ACE 
inlubitors or ARBs in this vascular pop-
ulation, but beta blockers, calcium channel 
blockers, diuretics and centrally acting 
agents are often used in combination due 
to the refractory hypertension that occurs 
in these patients.s 
Although not formally studied in any 
comparative studies versus placebo, it 
would be standard practice for all patients 
with renovascular disease to be taking 
aspirin and/or another antiplatelet agent 
and a statin, both to delay renal disease 
progression and to reduce their high risk 
of cardiovascular mortality. 
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Endovastular treatment - definitely 
not for all 
The effect of endovascular treatment of 
RAS on blood pressure reduction has 
been studied in more than 60 uncontrolled 
studies. Controlled studies have now invol-
ved more than 1000 unselected patients 
with renovascuJar disease randomised to 
medical treatment or renal angioplasty, 
with or without stenting (the largest of 
these studies being the ASTRAL studyV 
There has been no difference in either 
blood pressure reduction or renal decline 
after 12 months when medical therapy 
has been compared with revascularisation 
overall. Disappointingly, the adverse 
event rate in those undergoing angioplasty 
has ranged from 10 to 25% in the con-
trolled studies, indicating that angioplasty 
is not without serious complications. 
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Renal artery stenosis and hypertension 
continued 
Figure 2. Stant placed in the left.renal artery 
of an elderly woman with atherosclerotic 
renal artery stenosis. 
Since there is no level! evidence (that is, 
evidence from systematic review of rando-
mised controlled trials) supporting the use 
ofrevascularisation for unselected patients, 
it seems reasonable to restrict revascularl-
sation to those patients with high-grade 
lesions (that is, greater than 70% stenosis) 
associated with specific clinical problems 
(see the Table) in specialised centres 
(demonstrating low complication rates). 
In making a decision regarding endo-
vascular intervention in renovascular 
disease, clinicians must also consider the 
age of the patient and relative prognosis 
regarding other comorbidities- fur exam-
ple, a conservative approach is probably 
appropriate for older patients. 
When the clinical decision to revascu-
larise has been reached, the procedure 
of choice in patients with atherosclerotic 
RAS is renal artery stenting,(Figure 2), 
with or without a distal protection device 
(a device that prevents intraluminal chol-
esterol from seeding and damaging the 
kidtley downstrean1 from the angioplasty). 
This is because angioplasty alone has been 
associated with significant rates of resteno-
sis, and surgical revascularisation is very 
expensive and has no proven benefit over 
medical or endoluminal therapy.4 
There have been no studies of revascu-
larisation in patients with mild or moder-
ate renal stenosis. It seen1s prudent to offer 
medical therapy early in these individuals, 
given the natural history of progressive 
stenosis in atherosclerotic renal disease. 
Fibromuscular dysplasia should be 
treated by balloon angioplasty alone, based 
on currently available uncontrolled data! 
The flowchart on page 28 summarises 
the steps in the diagnosis and manage-
ment of RAS based on the evidence 
reviewed in both the CARl guidelines and 
a recent New England Journal of Medicine 
review.M 
Case study continued 
Based on this patient's poorly amtrolled 
hypertension and the evidence of renal 
damage with a shrunken kidney, protein-
uria, reduced eGFR and probable high RI 
(not dear due to a poorly performed ultra-
sound), a renal specialist became involved. 
Angiography, with the use of very little 
contrast and prior nephroprotective strate-
gies, was undertaken and demonstrated a 
near occluded RAS on the side of the 
shrunken kidney but only a 50% stenosis 
on the 10 em kidney side. Because of this 
patient's age and these findings, angio-
plasty was not carried out. The renal spe-
cialist became involved in the aggressive 
medical control of this man's refractory 
hypertension and his high, long-term 
car·diovascular risk. 
Conclusion 
The number of patients diagnosed with 
renovascular disease is likely to increase 
·with the rising incidence of hypertension 
and diabetes in our population. Although 
the imaging modalities fur renal artery dis-
ease have improved, their side effects need 
to be balanced against their improved sen-
sitivity when considering their use. 
Medical therapy with multiple medi-
cations is probably as effective in the 
nonselected population of patients with 
renovascular disease as interventional 
therapies. Only in carefully selected 
patients and under specific circum-
stances should angioplasty, ·with or with-
out stenting (depending on the RAS 
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aetiology), be considered and its benefits 
carefully balanced against its risks. MT 
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